Mercury Pharmaceuticals UK

Mar 2026

Systematic review identifies stress-induced biological triggers in oncology

Stress is a constant companion in the oncologist's office. It appears at the time of diagnosis, increases with each stage of treatment, and often does not resolve even after therapy formally ends. It accompanies therapeutic decisions, waiting for test results, fear of recurrence, and changes in daily functioning. Studies show that chronic stress can trigger biological processes that promote disease progression and weaken the body's defenses.

Mar 2026

iXCells Biotechnologies joins international collaboration to evaluate chemotherapeutic toxicity in human organoids

iXCells Biotechnologies ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, today announced it has entered an international collaboration with Rosebud Biosciences ("Rosebud"), Kantify, and Incite to evaluate off-target chemotherapeutic toxicities in patient-specific organoids.

Mar 2026

Optibrium introduces graphical interface for QuanSA to enhance ligand-based affinity predictions

Optibrium, a leading developer of software and AI solutions for molecular design, today announced a new QuanSA™ plugin for PyMOL, providing an intuitive Graphical User Interface (GUI) for its ligand-based binding affinity prediction method, part of the Company's BioPharmics 3D molecular modelling platform.

Mar 2026

Primerdesign partners with Origin Sciences to create novel rectal mucosal extraction workflow

Primerdesign (part of the Novacyt Group), a company focused on the design, manufacture, validation and supply of nucleic acid extraction and real-time PCR kits, and Origin Sciences (Origin), a company pioneering the detection and diagnosis of gastrointestinal (GI) disease through an unprecedented focus on a unique biospecimen: rectal mucus; today announced a strategic partnership to create a new protocol that optimizes DNA extraction from novel rectal mucosal samples.

Mar 2026

Navigating the moral landscape of pediatric AI surgery

Technological innovation has always driven surgical progress, and AI now represents the next transformative wave. Machine learning models are now being developed to predict surgical risks, assist in diagnosing rare congenital disorders, analyze imaging data, and anticipate postoperative complications. Risk prediction tools have already shifted from traditional statistical methods to more complex machine learning approaches, improving their ability to account for nonlinear interactions.